Menu Search
Equities

Elanco Animal Health Inc

ELAN:NYQ

Elanco Animal Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)14.07
  • Today's Change-0.43 / -2.97%
  • Shares traded6.32m
  • 1 Year change+29.68%
  • Beta1.4315
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Elanco Animal Health Inc's net income fell 1,478.21% from a loss of 78.00m to a larger loss of 1.23bn despite flat revenues.
Gross margin54.69%
Net profit margin4.60%
Operating margin16.03%
Return on assets1.48%
Return on equity3.24%
Return on investment1.64%
More ▼

Cash flow in USDView more

In 2023, Elanco Animal Health Inc did not generate a significant amount of cash. However, the company earned 271.00m from its operations for a Cash Flow Margin of 6.14%. In addition the company used 169.00m on investing activities and also paid 83.00m in financing cash flows.
Cash flow per share1.76
Price/Cash flow per share7.96
Book value per share13.20
Tangible book value per share-4.27
More ▼

Balance sheet in USDView more

Elanco Animal Health Inc has a Debt to Total Capital ratio of 40.05%, a lower figure than the previous year's 95.70%.
Current ratio2.55
Quick ratio1.31
Total debt/total equity0.6679
Total debt/total capital0.4005
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -1,465.36%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		117.58
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.